MedPath

The outcome of Remdesivir and Tocilizumab in COVID 19.

Not Applicable
Conditions
Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere
Registration Number
CTRI/2021/01/030341
Lead Sponsor
Seth G S Medical College and KEM Hospital Mumbai
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

1.Laboratory confirmed COVID 19 adults (Age > 18 years) admitted in KEM Hospital.

2.Patients in ICMR group 2B and onwards.

3.Received any of the following drugs alone or in combination: Remdesivir, Tocilizumab.

Exclusion Criteria

1. Suspected COVID 19 patients.

2. Positive patients in category 1A to 2A

3. Pregnant/Lactating patients.

4. Mortality within 24 hours of admission.

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath